How should hepatocellular disease be evaluated and managed?

Hepatocellular Disease: Evaluation and Management

Surveillance Strategy

Patients with cirrhosis from any cause should undergo 6-monthly abdominal ultrasound combined with serum α-fetoprotein (AFP) measurement for hepatocellular carcinoma (HCC) surveillance, unless they have Child-Pugh C cirrhosis and are not transplant candidates, or have ECOG performance status ≥2. 1, 2, 3

High-Risk Groups Requiring Surveillance

• All patients with established cirrhosis regardless of etiology (HBV, HCV, alcohol-related, hemochromatosis, primary biliary cirrhosis in males) 4, 3
• Chronic HBV patients without cirrhosis if they meet specific criteria:
  • Family history of HCC
  • Age >40 years with elevated ALT or HBV DNA >2,000 IU/mL
  • Asian, Pacific Islander, or sub-Saharan African background (start surveillance at age 30-35) 5, 6
• Stage F3 fibrosis (advanced non-cirrhotic fibrosis) based on individual risk assessment 6

Important caveat: Surveillance should not be offered to patients who cannot tolerate curative treatment due to severe liver dysfunction or poor performance status, as early detection provides no survival benefit in this context 1.

Diagnostic Approach

Imaging-Based Diagnosis (Non-Invasive)

For nodules ≥1 cm detected in cirrhotic patients, use multiphasic CT or MRI with extracellular contrast agents as first-line imaging, applying LI-RADS criteria for diagnosis. 7, 2, 1

The diagnostic hallmarks are:

• Arterial phase hyperenhancement (APHE)
• Washout appearance on portal venous or delayed phases
• Enhancing capsule (supportive feature)

Key technical points:

• Extracellular contrast agents are preferred over hepatocyte-specific agents (gadoxetic acid) for diagnostic accuracy 2
• LI-RADS LR-5 category confirms definite HCC with 91-100% specificity 7
• Contrast-enhanced ultrasound (CEUS) can serve as second-line imaging but should not replace CT/MRI initially due to inability to assess entire liver 2, 1

When to Perform Biopsy

Biopsy should be reserved for: 4, 1

• Patients without cirrhosis or chronic liver disease risk factors
• Nodules that do not meet imaging criteria for HCC (indeterminate lesions)
• When diagnosis would change management approach

Avoid biopsy in potentially resectable lesions due to 1-3% risk of needle tract seeding 4

Clinical Assessment at Diagnosis

Essential Initial Workup

Perform the following assessments immediately upon HCC diagnosis: 8, 1

1. Liver function evaluation:

   • Child-Pugh classification
   • Albumin, bilirubin, prothrombin time/INR
   • Platelet count

2. Portal hypertension assessment:

   • Upper endoscopy for varices
   • Clinical signs (ascites, splenomegaly, encephalopathy)

3. Tumor extent imaging:

   • Multiphasic CT or MRI of liver (number/size of nodules, vascular invasion)
   • Chest CT for metastases 4, 8
   • Consider bone scan only in advanced disease with symptoms

4. Viral hepatitis status:

   • HBV DNA quantification if HBsAg positive
   • HCV RNA if anti-HCV positive
   • Coinfection screening 8

5. Performance status: ECOG or WHO classification 9

6. Serum AFP level (prognostic, not diagnostic) 4, 1

Staging and Treatment Algorithm

Use the Barcelona Clinic Liver Cancer (BCLC) staging system to guide treatment decisions, as it incorporates tumor burden, liver function, and performance status. 9, 1, 10

Very Early/Early Stage (BCLC 0-A)

Single nodule <5 cm or up to 3 nodules each <3 cm with preserved liver function (Child-Pugh A-B):

1. Liver transplantation is preferred for cirrhotic patients meeting Milan criteria (single ≤5 cm or ≤3 nodules each ≤3 cm) 4, 11, 4

   • Provides treatment for both cancer and underlying cirrhosis
   • 5-year survival 50-75% 9

2. Hepatic resection for:

   • Non-cirrhotic livers (including fibrolamellar variant) 4
   • Highly selected Child-Pugh A cirrhotic patients unsuitable for transplant
   • Warning: High risk of postoperative decompensation in cirrhosis; requires expert hepatobiliary center 4

3. Percutaneous ablation (radiofrequency or microwave):

   • Best for peripheral lesions <3 cm 4
   • Alternative when surgery not feasible

Intermediate Stage (BCLC B)

Large or multifocal HCC without vascular invasion, Child-Pugh A-B, ECOG 0:

Transarterial chemoembolization (TACE) is the primary treatment 4, 9

• Produces tumor necrosis and improves survival in selected patients with good liver reserve
• Effective for symptom control (pain, bleeding)
• 3-year survival approximately 50% without treatment, improved with TACE 9

Consider systemic therapy for patients with large intrahepatic tumor burden despite intermediate stage classification 12

Advanced Stage (BCLC C)

Vascular invasion, extrahepatic spread, or cancer-related symptoms:

Immune checkpoint inhibitor-based combination therapy (atezolizumab plus bevacizumab) is now first-line systemic treatment, replacing sorafenib 12, 13

• Demonstrates superior overall survival compared to sorafenib
• Median survival approximately 50% at 1 year without treatment 9

Contraindications to systemic therapy:

• Avoid bevacizumab in patients with high-risk varices or recent variceal bleeding
• Systemic chemotherapy with traditional agents has poor response rates and should only be used in clinical trials 4

End Stage (BCLC D)

Child-Pugh C cirrhosis or ECOG ≥2:

Best supportive care only - median survival <3 months 9

Critical Management Principles

Multidisciplinary Team Approach

All HCC patients should be evaluated by a multidisciplinary team including hepatology, surgical oncology, interventional radiology, medical oncology, transplant surgery, and radiation oncology before treatment decisions 8, 14, 1, 15

Antiviral Therapy Integration

Patients with chronic HBV should receive nucleoside/nucleotide analogues to:

• Reduce HCC recurrence risk post-treatment 2
• Enable transplant candidacy (previously contraindicated with active viral replication) 4
• Prevent hepatic decompensation

Patients with HCV and fibrosis should receive direct-acting antivirals to reduce cirrhosis complications including HCC 2

Common Pitfalls to Avoid

1. Do not apply non-invasive imaging criteria to non-cirrhotic patients - requires biopsy confirmation 2, 1
2. Do not use tamoxifen - controlled trials show no survival benefit 4
3. Do not biopsy potentially resectable lesions unless diagnosis unclear - risk of seeding 4
4. Do not offer surveillance to Child-Pugh C patients ineligible for transplant - no benefit from early detection 1
5. Do not assume all intermediate-stage patients benefit from TACE - those with massive tumor burden may benefit more from systemic therapy 12

Surveillance Limitations

Patients should be counseled that despite improved early detection with surveillance, there is no definitive proof of survival benefit or cost-effectiveness 4. However, the consensus supports surveillance based on the availability of effective early-stage treatments and biological plausibility.